2250 Phase II trial of neoadjuvant gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy in resectable pancreatic adenocarcinoma. A GEMCAD 10–03 trial
EUROPEAN JOURNAL OF CANCER(2015)
Key words
resectable pancreatic adenocarcinoma,neoadjuvant gemcitabine,radiotherapy,gemcitabine-erlotinib
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined